Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 565 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: cyclosporine Clear all
Completed Phase 1Phase 2 Interventional

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

NCT00005851
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, laboratory biomarker analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Aurora, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

NCT00004482
View directory record Official record
Conditions
Myocarditis, Giant Cell Myocarditis
Interventions
Cyclosporine, methylprednisolone, Muromonab-CD3, prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

NCT01467505
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 4 Interventional

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

NCT00520260
View directory record Official record
Conditions
Dry Eye Disease, Ocular Comfort
Interventions
bromfenac, ketorolac
Drug
Lead sponsor
Florida Eye Microsurgical Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Oct 17, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

NCT07874490
View directory record Official record
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia

NCT00029380
View directory record Official record
Conditions
Hematologic Diseases, Anemia, Sickle Cell, Beta-Thalassemia, Hematopoietic Stem Cell Transplantation
Interventions
Sangstat, Cyclophosphamide, Busulfan, Mycophenolate Mofetil, Cyclosporine, Cord Blood Transplantation
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
14
States / cities
Oakland, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated Phase 1 Interventional

Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus

NCT00325741
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Hematopoietic Cell Transplantation
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 64 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional

Freedom Study: Myfortic in Kidney Transplant Patients

NCT00101738
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated Phase 3 Interventional

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

NCT00005113
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Cyclosporine, Sirolimus, Tacrolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

NCT00079391
View directory record Official record
Conditions
Hematologic Malignancies, Bone Marrow Transplant Rejection
Interventions
allogeneic hematopoietic stem cell transplantation
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)

NCT00745420
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hematopoietic Stem Cell Transplantation
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

NCT00097968
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Los Angeles, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00397813
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
3
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 4 Interventional

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation
Interventions
tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2007 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

NCT02013791
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Vehicle, Sham, Cyclosporine New Ophthalmic Formulation
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Artesia, California • Glendale, California • Irvine, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

NCT00611403
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®), Artificial Tears REFRESH ENDURA®
Drug
Lead sponsor
Allergan
Industry
Eligibility
21 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2011 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

NCT00008203
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, recombinant interferon gamma, carboplatin, cyclophosphamide, cyclosporine, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 17, 2026, 5:57 PM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

NCT00009776
View directory record Official record
Conditions
Lymphoma
Interventions
monoclonal antibody Lym-1, cyclosporine, paclitaxel, indium In 111 monoclonal antibody Lym-1, yttrium Y 90 monoclonal antibody Lym-1
Biological · Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

NCT00983060
View directory record Official record
Conditions
Chronic Hepatitis C Genotype-1 Relapse
Interventions
NIM811, Placebo BID + SOC
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
San Diego, California • Orlando, Florida • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine Disposition and Cyclosporine

NCT01648270
View directory record Official record
Conditions
Healthy
Interventions
buprenorphine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02276001
View directory record Official record
Conditions
Healthy
Interventions
K-877, Cyclosporine
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Predicting Response to Standardized Pediatric Colitis Therapy

NCT01536535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy
Drug · Other · Procedure
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 17 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 17, 2026, 5:57 PM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 17, 2026, 5:57 PM EDT